GLAXO Pharmaceuticals: Major
Health Technology
Mkt Cap
110.3B
P/E (TTM)
10.75
EPS
31.48
ROE
31.52%
Div Yield
4.91%
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Return on Equity (ROE) | 32.37% | 26.17% | 2.50% | 11.72% | 27.84% | |
| Return on Assets (ROA) | 20.61% | 15.48% | 1.44% | 7.46% | 18.94% | |
| Return on Invested Capital | 32.12% | 26.03% | 2.49% | 11.70% | 27.81% | |
| Gross Margin | 34.81% | 23.63% | 6.15% | 16.53% | 25.45% | |
| Operating Margin | 23.67% | 13.19% | -6.65% | 4.54% | 15.02% | |
| EBITDA Margin | 25.76% | 15.04% | -4.78% | 6.51% | 17.14% | |
| Net Margin | 15.21% | 10.68% | 1.08% | 5.89% | 14.61% | |
| Pre-Tax Margin | 25.32% | 17.12% | 4.25% | 12.20% | 20.25% | |
| Liquidity | ||||||
| Current Ratio | 2.32 | 2.06 | 1.74 | 1.82 | 2.28 | |
| Quick Ratio | 1.43 | 1.26 | 0.91 | 1.04 | 1.42 | |
| Leverage | ||||||
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | |
| Debt / Assets | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | |
| LT Debt / Equity | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | |
| LT Debt / Assets | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Debt | -9.28B | -7.56B | -4.27B | -5.97B | -8.75B | |
| Total Debt | 368.11M | 173.65M | 151.97M | 61.93M | 53.60M | |
| Efficiency | ||||||
| Asset Turnover | 1.35 | 1.45 | 1.34 | 1.27 | 1.30 | |
| Inventory Turnover | 3.40 | 3.90 | 4.19 | 4.06 | 4.05 | |
| Per Share | ||||||
| Book Value Per Share | 105.74 | 88.79 | 68.06 | 66.11 | 65.90 | |
| Tangible Book Per Share | 102.74 | 85.79 | 65.06 | 63.11 | 62.78 | |
| Cash Per Share | 30.28 | 24.30 | 13.87 | 18.95 | 27.64 | |
| Total Debt Per Share | 1.16 | 0.55 | 0.48 | 0.19 | 0.17 | |
| Working Capital Per Share | 62.87 | 49.51 | 33.84 | 33.27 | 33.41 | |
| Shares & Market | ||||||
| Total Shares Outstanding | 318,467,278 | 318,467,278 | 318,467,278 | 318,467,278 | 318,467,278 | |
| Market Cap | 124.13B | 126.40B | 26.43B | 27.95B | 43.47B | |
| Enterprise Value | 114.86B | 118.84B | 22.16B | 21.98B | 34.72B | |
| Employees | 1,606 | 1,690 | 1,708 | 1,635 | 1,771 | |
| Shareholders | 12,751 | 12,751 | 12,751 | 12,751 | 12,751 | |